The U.S. Food and Drug Administration (FDA) has cleared the first human trial for a gene therapy aimed at reversing age-related molecular damage, according to a social media post by Avi Roy. The therapy, designated ER-100 and developed by Life Biosciences, secured clearance in January 2026 to begin human trials. This marks a significant step in the field of age reversal, with the trial focusing on patients suffering from glaucoma or NAION, a form of sudden vision loss.
ER-100 is designed to deliver three specific Yamanaka reprogramming factors—OCT4, SOX2, and KLF4—directly into the eyes. These factors are molecular switches that, as demonstrated by Shinya Yamanaka in 2006, can revert adult cells to a stem-cell-like state. The underlying principle is partial reprogramming, which seeks to turn back the cellular clock sufficiently to restore function without causing cells to lose their specialized identities.
The clinical investigation is a Phase 1 trial, with its primary objective being the assessment of safety rather than efficacy. While the tweet mentioned a clinical trial identifier, NCT07290244, public databases did not immediately confirm this registration number. Prior animal studies, however, reportedly showed "significant reversal of age-related molecular damage across multiple tissues," as stated in the tweet.
The choice of the eye as the initial target for this groundbreaking therapy is strategic, as vision research often navigates the FDA clearance process more rapidly than systemic aging interventions. "The eye isn’t the end goal. It’s the entry point," Avi Roy's tweet explained, emphasizing that successful safety validation in the eye could pave the way for broader applications of the science. Life Biosciences has a stated mission to develop therapies for age-related diseases, attracting substantial investment for its focus on epigenetic reprogramming.
This development arrives after "20 years of promises about reversing aging," according to Roy's post, positioning the 2026 authorization as a pivotal moment. The company's work aligns with a growing scientific interest in leveraging cellular reprogramming to address the fundamental causes of aging and age-related conditions. The trial's progress will be closely watched by the scientific community and those hopeful for advancements in regenerative medicine.
